Prescribing Flashcards
1st line antiplatelet therapy for secondary prevention in medically treated ACS
Aspirin - lifelong
P2Y12 inhibitor e.g. ticagrelor (prasugrel, or clopidogrel) - 12 months
2nd line antiplatelet therapy for medically treated ACS
If aspirin contraindicated, lifelong clopidogrel
1st line antiplatelet therapy for secondary prevention following PCI
Aspirin - lifelong
No oral anticoagulant –> prasugrel/ticagrelor - 12 months
oral anticoagulant –> clopidogrel - 12 months
2nd line antiplatelet therapy for secondary prevention following PCI
If aspirin contraindicated, lifelong clopidogrel
1st line antiplatelet therapy for secondary prevention following fibrinolysis for STEMI
Aspirin - lifelong
Ticagrelor - unless high bleeding risk, up to 12 moths
2nd line antiplatelet therapy for secondary prevention following fibrinolysis for STEMI
If high bleeding risk –> clopidogrel for up to 12 months,
Or aspirin alone
Antiplatelet therapy in acute management of TIA
Aspirin 300mg oral loading dose
2nd line: clopidogrel 300mg oral loading dose
Antiplatelet therapy in acute management of STEMI
Aspirin - 300mg oral loading dose
1st line antiplatelet therapy for secondary prevention following TIA/ischaemic stroke
Clopidogrel - 75mg oral, once daily
2nd line antiplatelet therapy for secondary prevention following TIA/ischaemic stroke
If clopidogrel contraindicated/not tolerated –>
Aspirin - 75mg oral, od
+ Dipyramidole MR - 200mg, twice daily
When is clopidogrel used as a single agent anticoagulant?
In peripheral vascular disease, or CVA for secondary prevention
Monitoring for statins
LFTs
-Baseline
-3 months
-12 months
Monitoring for ACE-inhibitors
U+Es
- Prior to treatment
- After increasing dose
- Minimum annually
Monitoring for amioadrone
TFTs, LFTs, U+Es, CXR - prior to treatment
TFTs + LFTs - every 6 months
Monitoring for methotrexate
FBCs
LFTs
U+Es
Before starting treatment
Weekly until therapy stabilised
Then every 2-3 months
